Ibrutinib

Search with Google Search with Bing

Information
Drug Name
Ibrutinib
Description
Entry(CIViC)
4
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
chronic lymphocytic leukemia BTK p.Cys515Ser (p.C515S)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) BTK p.Cys515Ser (p.C515S)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) 		B Predictive Supports Resistance Somatic 4 26182309 Detail
chronic lymphocytic leukemia BTK p.Thr350Ala (p.T350A)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) BTK p.Thr350Ala (p.T350A)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) 		C Predictive Supports Resistance Somatic 4 27626698 Detail
chronic lymphocytic leukemia BTK p.Cys515Ser (p.C515S)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) BTK p.Cys515Ser (p.C515S)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) 		B Predictive Supports Resistance Somatic 4 24869598 Detail
Waldenström's Macroglobulinemia MYD88 p.Leu260Pro (p.L260P)
( ENST00000417037.8, ENST00000421516.3, ENST00000650112.2, ENST00000650905.2, ENST00000651800.2, ENST00000652213.1 ) MYD88 p.Leu260Pro (p.L260P)
( ENST00000417037.8, ENST00000421516.3, ENST00000650112.2, ENST00000650905.2, ENST00000651800.2, ENST00000652213.1 ) 		B Predictive Supports Sensitivity/Response Somatic 4 25853747 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
In a trial of 308 patients with chronic lymphocyti... BTK BTK p.Cys515Ser (p.C515S)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) BTK p.Cys515Ser (p.C515S)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Case report of a patient with CLL and Richter-tran... BTK BTK p.Thr350Ala (p.T350A)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) BTK p.Thr350Ala (p.T350A)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Whole exome sequencing of 6 chronic lymphocytic le... BTK BTK p.Cys515Ser (p.C515S)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) BTK p.Cys515Ser (p.C515S)
( ENST00000308731.8, ENST00000621635.4, ENST00000695614.1, ENST00000695615.1, ENST00000695617.1, ENST00000695622.1, ENST00000695623.1, ENST00000695625.1, ENST00000703407.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
A prospective study of ibrutinib in 63 symptomatic... MYD88 MYD88 p.Leu260Pro (p.L260P)
( ENST00000417037.8, ENST00000421516.3, ENST00000650112.2, ENST00000650905.2, ENST00000651800.2, ENST00000652213.1 ) MYD88 p.Leu260Pro (p.L260P)
( ENST00000417037.8, ENST00000421516.3, ENST00000650112.2, ENST00000650905.2, ENST00000651800.2, ENST00000652213.1 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03136497 Active, not recruiting Phase 1 A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma September 5, 2017 December 2022
NCT02537613 Active, not recruiting Phase 1 A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia December 2015 January 2029
NCT02251548 Active, not recruiting Phase 2 A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia October 2014 January 2026
NCT03964090 Active, not recruiting Phase 2 Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) June 27, 2019 July 1, 2026
NCT02242097 Active, not recruiting Phase 2 Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma January 12, 2015 January 2025
NCT01841723 Active, not recruiting Phase 2 Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia April 30, 2013 December 31, 2024
NCT04876092 Active, not recruiting Phase 1 A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL July 28, 2021 November 25, 2024
NCT02007044 Active, not recruiting Phase 2 Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia December 6, 2013 June 30, 2026
NCT02581930 Active, not recruiting Phase 2 Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma August 17, 2016 March 5, 2025
NCT04781855 Active, not recruiting Phase 1 Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation July 14, 2022 December 31, 2024
NCT01849263 Active, not recruiting Phase 2 Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma April 2, 2013 March 7, 2025
NCT04662255 Active, not recruiting Phase 3 Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) April 8, 2021 July 2026
NCT03939182 Active, not recruiting Phase 1 Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma May 29, 2019 May 2025
NCT03790332 Active, not recruiting Phase 1/Phase 2 Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) November 19, 2018 January 4, 2026
NCT02048813 Active, not recruiting Phase 3 Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma February 20, 2014 December 31, 2024
NCT02629809 Active, not recruiting Phase 2 Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia March 18, 2016 March 31, 2025
NCT03770416 Active, not recruiting Phase 2 Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma February 15, 2019 June 30, 2025
NCT04608318 Active, not recruiting Phase 3 Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) March 1, 2021 March 2027
NCT02315768 Active, not recruiting Phase 1/Phase 2 Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. August 26, 2015 November 2023
NCT01589302 Active, not recruiting Phase 2 PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia May 21, 2012 December 31, 2024
NCT02649387 Active, not recruiting Phase 2 Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy February 8, 2016 January 15, 2026
NCT03737981 Active, not recruiting Phase 3 Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia January 31, 2019 June 1, 2027
NCT05211336 Active, not recruiting Phase 1 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System April 19, 2022 June 1, 2029
NCT03734198 Active, not recruiting Phase 2 Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction December 19, 2018 June 2026
NCT05105841 Active, not recruiting Phase 2 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) November 8, 2021 October 26, 2025
NCT03710772 Active, not recruiting Phase 2 Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma May 1, 2019 May 22, 2025
NCT02682641 Active, not recruiting Phase 2 Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL May 18, 2016 December 2024
NCT01880567 Active, not recruiting Phase 2 Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma July 15, 2013 July 31, 2024
NCT03708003 Active, not recruiting Phase 2 Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL March 11, 2019 December 2026
NCT03703167 Active, not recruiting Phase 1 Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) January 22, 2019 November 2024
NCT03702725 Active, not recruiting Phase 1 Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma August 29, 2019 March 1, 2026
NCT04477486 Active, not recruiting Phase 2 Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma September 23, 2020 October 4, 2025
NCT03701282 Active, not recruiting Phase 3 Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia February 12, 2019 May 7, 2028
NCT02159755 Active, not recruiting Phase 1 Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma May 20, 2014 January 20, 2025
NCT03697512 Active, not recruiting Phase 2 MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas September 27, 2019 June 15, 2027
NCT02744612 Active, not recruiting Phase 2 Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma June 20, 2016 December 31, 2024
NCT04294641 Active, not recruiting Phase 2 Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease May 10, 2021 June 28, 2026
NCT02756897 Active, not recruiting Phase 2 Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia July 7, 2016 July 1, 2024
NCT03581942 Active, not recruiting Phase 1/Phase 2 Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) August 23, 2018 July 2025
NCT02160015 Active, not recruiting Phase 1 Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery May 20, 2014 July 31, 2024
NCT01776840 Active, not recruiting Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma May 2013 June 2024
NCT01886872 Active, not recruiting Phase 3 Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia December 9, 2013 January 30, 2025
NCT03535350 Active, not recruiting Phase 1 Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma August 24, 2018 December 31, 2024
NCT02787369 Active, not recruiting Phase 1 ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL May 2016 April 2027
NCT01955499 Active, not recruiting Phase 1 Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma September 24, 2013 December 31, 2024
NCT03513562 Active, not recruiting Phase 2 Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations March 26, 2019 December 31, 2024
NCT02824029 Active, not recruiting Phase 2 Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma June 2016 August 18, 2024
NCT02827617 Active, not recruiting Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia June 1, 2016 December 31, 2024
NCT04273139 Active, not recruiting Phase 2 Ibrutinib + Venetoclax in Untreated WM July 9, 2020 February 1, 2028
NCT05564052 Active, not recruiting Phase 2 A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma December 6, 2022 September 30, 2024
NCT02427451 Active, not recruiting Phase 1/Phase 2 Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia August 3, 2015 December 31, 2024
NCT02427620 Active, not recruiting Phase 2 Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma June 3, 2015 June 30, 2025
NCT03506373 Active, not recruiting Phase 2 Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia July 5, 2018 May 1, 2025
NCT01829568 Active, not recruiting Phase 1 Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma June 21, 2013 January 30, 2025
NCT04230304 Active, not recruiting Phase 2 Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study September 16, 2020 February 28, 2026
NCT02443077 Active, not recruiting Phase 3 Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma October 12, 2016 May 10, 2025
NCT03479268 Active, not recruiting Phase 1 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma March 22, 2018 June 22, 2024
NCT02446236 Active, not recruiting Phase 1 Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma June 18, 2015 December 2024
NCT02940301 Active, not recruiting Phase 2 Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma December 20, 2016 December 31, 2024
NCT03478514 Active, not recruiting Phase 2 Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma September 11, 2018 December 2025
NCT02947347 Active, not recruiting Phase 3 Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma January 2017 June 25, 2026
NCT03462719 Active, not recruiting Phase 3 A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) April 17, 2018 April 5, 2027
NCT04212013 Active, not recruiting Phase 3 A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma December 23, 2019 March 18, 2027
NCT02232386 Active, not recruiting Phase 2 Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia March 2, 2015 April 2024
NCT03447808 Active, not recruiting Phase 1 Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia August 16, 2018 December 31, 2024
NCT02956382 Active, not recruiting Phase 1/Phase 2 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma March 1, 2017 November 2024
NCT02471391 Active, not recruiting Phase 2 ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) July 22, 2015 June 2025
NCT03440567 Active, not recruiting Phase 1 Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma April 2, 2018 December 30, 2024
NCT03422393 Active, not recruiting Phase 1 Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib May 1, 2018 August 2028
NCT03282396 Active, not recruiting Phase 2 Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma June 8, 2020 February 28, 2026
NCT03207555 Active, not recruiting Phase 2 Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) May 23, 2018 August 31, 2025
NCT03021460 Active, not recruiting Phase 1 Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery January 31, 2017 December 31, 2024
NCT02477696 Active, not recruiting Phase 3 Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) July 28, 2015 January 3, 2028
NCT02514083 Active, not recruiting Phase 2 A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL December 9, 2015 October 23, 2028
NCT03204188 Active, not recruiting Phase 2 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma September 22, 2017 December 31, 2026
NCT03112174 Active, not recruiting Phase 3 Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) June 29, 2017 November 15, 2024
NCT02518555 Active, not recruiting Phase 2 Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma January 12, 2016 December 31, 2024
NCT01833039 Approved for marketing An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
NCT02436668 Completed Phase 3 Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) May 2015 April 25, 2019
NCT01578707 Completed Phase 3 A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia June 2012 October 25, 2018
NCT01599949 Completed Phase 2 A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy August 2012 May 2015
NCT01611090 Completed Phase 3 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma September 19, 2012 January 23, 2019
NCT01626651 Completed Phase 1 A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants June 2012 August 2012
NCT01646021 Completed Phase 3 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy December 10, 2012 December 15, 2016
NCT01674322 Completed Phase 1 A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants August 2012 September 2012
NCT01722487 Completed Phase 3 Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL March 2013 May 2015
NCT01724346 Completed Phase 3 Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma August 28, 2012 August 17, 2023
NCT01744691 Completed Phase 2 A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion January 2013 April 2016
NCT01855750 Completed Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma September 3, 2013 April 5, 2019
NCT01886859 Completed Phase 1 Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma April 26, 2013 September 21, 2022
NCT01962792 Completed Phase 1/Phase 2 Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma December 2013 March 2019
NCT01973387 Completed Phase 3 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma October 28, 2013 August 11, 2017
NCT01980628 Completed Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma December 2013 October 2, 2017
NCT01980654 Completed Phase 2 Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma December 2013 November 2017
NCT02013128 Completed Phase 1/Phase 2 Ublituximab + Ibrutinib in Select B-cell Malignancies January 6, 2014 December 2015
NCT02077166 Completed Phase 1/Phase 2 Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma March 13, 2014 December 17, 2020
NCT02142049 Completed Phase 1/Phase 2 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma May 2014 August 2017
NCT02165397 Completed Phase 3 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia July 7, 2014 November 7, 2019
NCT02169180 Completed Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma August 2014 December 2016
NCT02195869 Completed Phase 1/Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease July 14, 2014 September 15, 2017
NCT02207062 Completed Phase 2 Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma October 2014 November 1, 2023
NCT02219737 Completed Phase 1 Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma September 12, 2014 May 11, 2017
NCT02264574 Completed Phase 3 A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) October 6, 2014 September 3, 2019
NCT02268851 Completed Phase 1 A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL November 2014 August 2023
NCT02271438 Completed Phase 1 A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants October 2014 May 2015
NCT02301156 Completed Phase 3 Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) January 27, 2015 April 1, 2020
NCT02309580 Completed Phase 1 Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma January 2015 May 8, 2023
NCT02321540 Completed Phase 1/Phase 2 A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer March 31, 2015 September 16, 2021
NCT02329847 Completed Phase 1/Phase 2 A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies March 11, 2015 February 9, 2022
NCT02332980 Completed Phase 2 Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas February 19, 2015 January 4, 2022
NCT02345863 Completed Phase 2 Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients January 16, 2015 March 29, 2019
NCT02352558 Completed Phase 1 A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies May 2015 May 16, 2019
NCT02381080 Completed Phase 1 Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy May 19, 2015 June 24, 2016
NCT02401048 Completed Phase 1/Phase 2 A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas May 2015 November 2017
NCT02403271 Completed Phase 1/Phase 2 A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors March 2015 August 2017
NCT02406742 Completed Phase 1/Phase 2 A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma July 27, 2015 July 7, 2020
NCT02420912 Completed Phase 2 Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation June 19, 2015 February 14, 2022
NCT01325701 Completed Phase 2 Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma May 2011 October 2014
NCT02460276 Completed Phase 2 A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma April 2015 December 31, 2019
NCT02532257 Completed Phase 2 Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma April 11, 2016 August 15, 2023
NCT02542514 Completed Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma September 2015 December 1, 2021
NCT02553941 Completed Phase 1 Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome May 17, 2016 November 7, 2019
NCT02556892 Completed Phase 1 A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma July 3, 2015 August 20, 2018
NCT02562898 Completed Phase 1/Phase 2 Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer October 12, 2015 September 1, 2020
NCT02575300 Completed Phase 2 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors October 9, 2015 November 4, 2019
NCT02582320 Completed Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program March 2016 October 3, 2018
NCT02599324 Completed Phase 1/Phase 2 Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors December 1, 2015 August 20, 2021
NCT02604511 Completed Phase 2 Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing January 2016 November 1, 2022
NCT02626884 Completed Phase 2 Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) August 2016 August 2020
NCT02636322 Completed Phase 2 Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib March 29, 2016 October 24, 2022
NCT02638116 Completed Phase 1 A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults January 2016 March 2016
NCT02643667 Completed Phase 2 Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer July 2016 April 12, 2023
NCT02666898 Completed Phase 2 Phase II Trial GA101 Inbrutinib B CLL October 2015 March 2018
NCT02670616 Completed Phase 2 Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma May 1, 2016 October 2020
NCT02689141 Completed Phase 2 Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) February 4, 2016 February 6, 2020
NCT02733042 Completed Phase 1/Phase 2 A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia May 11, 2016 August 21, 2022
NCT02736617 Completed Phase 2 Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma July 5, 2016 June 2, 2021
NCT02756247 Completed Phase 1 A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma May 9, 2016 October 6, 2022
NCT02758665 Completed Phase 2 Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL September 2016 March 2022
NCT02759016 Completed Phase 1 Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib June 23, 2016 July 9, 2019
NCT02760485 Completed Phase 1/Phase 2 A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma December 29, 2016 June 6, 2022
NCT02801578 Completed Phase 2/Phase 3 A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) July 6, 2016 January 28, 2019
NCT02863718 Completed Phase 3 Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression April 30, 2014 July 11, 2022
NCT02869633 Completed Phase 2 Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant November 2016 October 2023
NCT02874404 Completed Phase 2 TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma October 7, 2016 July 1, 2019
NCT02877225 Completed Phase 1 Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule August 29, 2016 November 11, 2016
NCT02899078 Completed Phase 1/Phase 2 Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer November 15, 2016 February 24, 2021
NCT02902965 Completed Phase 2 Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma September 20, 2016 October 26, 2018
NCT02910583 Completed Phase 2 Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) September 28, 2016 March 27, 2024
NCT02927964 Completed Phase 1/Phase 2 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma November 7, 2016 May 18, 2023
NCT02950051 Completed Phase 3 Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation December 13, 2016 February 29, 2024
NCT02950220 Completed Phase 1 Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma January 12, 2017 January 3, 2019
NCT02959944 Completed Phase 3 Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) May 11, 2017 July 12, 2021
NCT03045328 Completed Phase 2 Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL September 26, 2017 August 5, 2021
NCT03053440 Completed Phase 3 A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) January 25, 2017 June 21, 2022
NCT03112603 Completed Phase 3 A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) June 29, 2017 December 15, 2022
NCT03149315 Completed Phase 2 Inhibition of Anaphylaxis by Ibrutinib April 10, 2017 November 14, 2018
NCT03219047 Completed Early Phase 1 Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma December 20, 2018 July 3, 2023
NCT03267186 Completed Phase 2 Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant September 12, 2017 April 30, 2021
NCT03301207 Completed Phase 1 A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy October 20, 2017 December 4, 2018
NCT03310619 Completed Phase 1/Phase 2 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies December 20, 2017 February 15, 2023
NCT03323151 Completed Phase 1/Phase 2 A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma August 13, 2018 September 7, 2023
NCT03332498 Completed Phase 1/Phase 2 Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers January 24, 2018 September 9, 2021
NCT03359460 Completed Phase 1 Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome December 1, 2017 November 17, 2019
NCT03424122 Completed Phase 1 INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) July 2, 2018 June 27, 2022
NCT03425591 Completed A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice May 11, 2016 August 11, 2022
NCT03454165 Completed Phase 1 A Study of BNC105P Combined With Ibrutinib March 9, 2018 January 14, 2021
NCT03474679 Completed Phase 3 A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) May 1, 2018 November 29, 2021
NCT03476655 Completed Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India April 28, 2018 May 31, 2019
NCT03525925 Completed Phase 1 Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors July 18, 2018 July 31, 2022
NCT03720561 Completed A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting October 30, 2018 November 12, 2021
NCT03734016 Completed Phase 3 A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia November 1, 2018 February 28, 2024
NCT03755947 Completed Phase 2 Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia December 1, 2018 February 1, 2021
NCT03873493 Completed Phase 2 A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia January 14, 2020 November 4, 2021
NCT03877055 Completed Phase 1/Phase 2 A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma March 13, 2019 October 7, 2022
NCT04042376 Completed Phase 4 A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) December 18, 2019 March 19, 2024
NCT04062448 Completed Phase 2 A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) September 25, 2019 March 2, 2023
NCT04274738 Completed Phase 1 A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 April 30, 2020 October 31, 2022
NCT04375397 Completed Phase 2 Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury June 6, 2020 June 8, 2021
NCT04439006 Completed Phase 1 Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization October 23, 2020 September 20, 2022
NCT05052385 Completed ECP Combination Study April 13, 2021 June 15, 2022
NCT01804686 Enrolling by invitation Phase 3 A Long-term Extension Study of PCI-32765 (Ibrutinib) September 9, 2013 January 29, 2027
NCT03229200 Enrolling by invitation Phase 4 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. May 22, 2017 July 2, 2027
NCT06271616 Not yet recruiting Phase 2 Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant June 1, 2024 June 30, 2027
NCT06357676 Not yet recruiting Phase 1/Phase 2 Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma May 1, 2024 May 1, 2029
NCT03960840 Recruiting Phase 1/Phase 2 Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL June 26, 2019 June 30, 2027
NCT04739813 Recruiting Phase 1 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma July 9, 2021 July 15, 2029
NCT06299540 Recruiting Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia May 15, 2024 September 30, 2026
NCT05963074 Recruiting Phase 2 A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia January 31, 2024 March 19, 2029
NCT04421560 Recruiting Phase 1/Phase 2 Pembrolizumab, Ibrutinib and Rituximab in PCNSL August 1, 2020 March 5, 2025
NCT05998642 Recruiting Phase 2 Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma February 13, 2024 December 31, 2028
NCT04398459 Recruiting Phase 2 The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia May 1, 2020 June 30, 2025
NCT04129710 Recruiting Phase 2 A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) January 1, 2020 December 31, 2025
NCT05254743 Recruiting Phase 3 A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) July 22, 2022 August 2028
NCT02436707 Recruiting Phase 2 Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma October 27, 2015 December 31, 2026
NCT04840602 Recruiting Phase 2 Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma January 5, 2022 March 31, 2028
NCT04263480 Recruiting Phase 2 Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia February 18, 2021 February 2028
NCT03328078 Recruiting Phase 1/Phase 2 A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma December 28, 2017 August 2026
NCT06136559 Recruiting Phase 3 A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) December 13, 2023 September 30, 2032
NCT03223610 Recruiting Phase 1/Phase 2 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma February 9, 2018 December 1, 2026
NCT03220022 Recruiting Phase 1 Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas March 16, 2018 June 20, 2025
NCT04771507 Recruiting Phase 1/Phase 2 A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) February 23, 2018 December 1, 2027
NCT03198026 Recruiting Phase 2 Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas February 20, 2018 February 20, 2031
NCT03153202 Recruiting Phase 1/Phase 2 Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) July 14, 2017 December 2025
NCT03128879 Recruiting Phase 2 Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL June 16, 2017 June 1, 2025
NCT02315326 Recruiting Phase 1/Phase 2 Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) December 2014 December 2026
NCT03731234 Recruiting Phase 2 Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance July 2, 2019 July 2027
NCT04758975 Recruiting Phase 2 Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) September 19, 2022 December 30, 2027
NCT02997761 Recruiting Phase 2 Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia June 27, 2017 September 2025
NCT04494503 Recruiting Phase 1/Phase 2 Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL August 31, 2020 December 2025
NCT04450173 Recruiting Phase 2 Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma February 24, 2021 April 2025
NCT04446962 Recruiting Phase 1/Phase 2 LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) October 30, 2020 January 15, 2031
NCT05864742 Recruiting Phase 2 Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma September 7, 2023 June 1, 2029
NCT05672173 Recruiting Phase 2 Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation June 2, 2023 September 10, 2025
NCT05106296 Recruiting Phase 1 Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer February 8, 2022 September 2026
NCT05283720 Recruiting Phase 2 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma June 14, 2022 November 26, 2032
NCT04522284 Recruiting Phase 1/Phase 2 PRECISE CURATE.AI Pilot Clinical Trial August 20, 2020 August 1, 2023
NCT05782374 Recruiting Real World Data on Ibrutinib Use in PCNSL Rel/Ref August 10, 2022 August 10, 2023
NCT04607772 Suspended Phase 1/Phase 2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) November 18, 2020 December 2025
NCT03225716 Terminated Phase 1 A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia October 20, 2017 December 31, 2022
NCT02129062 Terminated Phase 2 Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia April 2014 November 2015
NCT02966730 Terminated Early Phase 1 Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy November 2016 June 20, 2019
NCT02954406 Terminated Phase 1 A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma March 5, 2017 July 27, 2020
NCT02109224 Terminated Phase 1 Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection September 2014 July 2015
NCT02943473 Terminated Phase 2 Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients May 18, 2017 September 10, 2019
NCT03514017 Terminated Phase 2 Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia May 31, 2019 May 16, 2023
NCT03679624 Terminated Phase 2 Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia July 30, 2020 October 13, 2020
NCT03684694 Terminated Phase 1/Phase 2 Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma December 1, 2018 November 8, 2022
NCT03689894 Terminated Phase 1/Phase 2 Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT April 11, 2019 September 20, 2021
NCT02703272 Terminated Phase 3 A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma July 1, 2016 June 11, 2021
NCT02670317 Terminated Phase 2 Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. September 2016 February 2017
NCT02635074 Terminated Phase 1 Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia November 2016 November 10, 2017
NCT02614508 Terminated Phase 1 Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia January 2016 August 2019
NCT03876028 Terminated Phase 1 Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients June 11, 2019 November 1, 2021
NCT02548962 Terminated Phase 1/Phase 2 Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma March 2016 June 13, 2018
NCT04016805 Terminated Phase 2 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax August 5, 2019 May 22, 2022
NCT04209621 Terminated Phase 2 Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma July 31, 2020 January 22, 2021
NCT02451111 Terminated Phase 2 Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma November 6, 2015 July 15, 2023
NCT04235036 Terminated Phase 2 Ibrutinib and Rituxan for Chronic GVHD December 16, 2019 December 23, 2022
NCT02415608 Terminated Phase 2 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis March 2015 June 14, 2017
NCT02356458 Terminated Phase 1/Phase 2 Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma August 31, 2015 March 30, 2021
NCT02351037 Terminated Phase 2 Study of Ibrutinib in Subjects With Acute Myeloid Leukemia February 2015 April 2017
NCT03121534 Terminated Phase 2 Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation June 22, 2017 February 11, 2022
NCT03145480 Terminated Phase 2 Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients June 19, 2017 September 28, 2018
NCT03093831 Terminated Phase 2 Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma July 8, 2016 July 17, 2020
NCT03015792 Terminated Phase 1/Phase 2 Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant March 10, 2017 October 18, 2022
NCT02272686 Terminated Phase 2 Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma June 3, 2016 December 22, 2017
NCT02269085 Terminated Phase 1 Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma April 20, 2015 May 29, 2018
NCT03400176 Terminated Phase 1 VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib April 9, 2018 September 29, 2023
NCT03827603 Unknown status Phase 2 Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia February 21, 2017 March 31, 2022
NCT02303392 Unknown status Phase 1 Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma March 11, 2015 December 31, 2022
NCT02884453 Unknown status Phase 2 Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma July 19, 2016 December 30, 2021
NCT02991638 Unknown status Phase 3 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers November 1, 2016 June 2021
NCT02689869 Unknown status Phase 2 Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma April 2016 July 2022
NCT02692248 Unknown status Phase 2 Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation April 7, 2016 September 2020
NCT02912754 Unknown status Phase 1/Phase 2 Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients March 2017 August 2019
NCT03642236 Unknown status Phase 2/Phase 3 Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML August 2018 September 2023
NCT02757040 Unknown status Phase 3 Combination of Ibrutinib and As2O3 in the Treatment of CLL December 2016 December 2018
NCT04094051 Unknown status Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice October 1, 2019 December 31, 2021
NCT04025593 Unknown status Phase 2 Biomarker Guided Treatment in DLBCL July 17, 2019 June 1, 2023
NCT03949062 Unknown status Phase 2 Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL March 13, 2019 May 2022
NCT04514393 Unknown status Phase 2 Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma October 10, 2020 June 1, 2024
NCT04685915 Withdrawn Phase 2 Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL February 18, 2021 March 1, 2028
NCT02735876 Withdrawn Phase 3 A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma May 2016
NCT02743546 Withdrawn Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma July 20, 2016 March 31, 2020
NCT02815059 Withdrawn Phase 1 Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone September 28, 2016 January 9, 2018
NCT02662296 Withdrawn Phase 2 Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant March 2016
NCT05431179 Withdrawn Phase 3 A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma March 2023 December 2026
NCT03617484 Withdrawn Phase 2 Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma July 2020 July 2030
NCT02677948 Withdrawn Phase 1/Phase 2 Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) October 2016 October 2018
NCT03130348 Withdrawn Phase 2 Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis March 15, 2018 April 2022
NCT03232307 Withdrawn Phase 2 Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma July 1, 2019 July 1, 2021
NCT02611908 Withdrawn Phase 1 Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. June 2016 November 2020
NCT04665115 Withdrawn Phase 2 Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) November 23, 2020 July 22, 2022
NCT02780830 Withdrawn Phase 1 AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma June 2016 April 2019
NCT03943342 Withdrawn Phase 2 Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance March 11, 2020 July 20, 2021
NCT04043845 Withdrawn Phase 1 ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies February 3, 2020 February 3, 2020
NCT02950038 Withdrawn Phase 2 Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) December 2016